PARTNERING
CureVac intends to maximize the commercial potential of its RNActive®-based drug candidates by partnering with biotechnological and pharmaceutical companies. The Company is well positioned to enter co-development and in-licensing agreements involving novel antigenic targets, e.g. tumour-specific or tumour-associated antigens to be integrated in its RNActive® technology platform.To secure its position as a leader in mRNA-based therapeutics, the Company has devised an IP strategy ensuring broad international intellectual property rights covering its core technologies, composition of matter as well as clinical use and therapeutic applications.
